Number needed to treat for interleukin inhibitors approved for the treatment of moderate-to-severe plaque psoriasis in Italy.

IF 0.4 Q4 HEALTH CARE SCIENCES & SERVICES Global & Regional Health Technology Assessment Pub Date : 2021-01-01 DOI:10.33393/grhta.2021.2222
Roberto Ravasio, Antonio Costanzo, Silvia Antonelli, Alessia Maiorino, Serena Losi
{"title":"Number needed to treat for interleukin inhibitors approved for the treatment of moderate-to-severe plaque psoriasis in Italy.","authors":"Roberto Ravasio,&nbsp;Antonio Costanzo,&nbsp;Silvia Antonelli,&nbsp;Alessia Maiorino,&nbsp;Serena Losi","doi":"10.33393/grhta.2021.2222","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Interleukin (IL) inhibitors achieve greater levels of efficacy than older systemic therapies. We calculated the number needed to treat (NNT) of ixekizumab compared with other IL inhibitors approved in Italy for the treatment of moderate-to-severe plaque psoriasis.</p><p><strong>Methods: </strong>The clinical efficacy was evaluated in terms of NNT, based on the results of a recent network meta--analysis (NMA) by the Cochrane Database of Systematic Reviews. The NMA investigated many systemic and biological treatments, but this analysis compared only the efficacy of the following IL inhibitors - brodalumab, guselkumab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab - for patients with moderate-to-severe plaque psoriasis. Drugs were compared and ranked according to effectiveness considering the PASI (Psoriasis Area and Severity Index) 90 score.</p><p><strong>Results: </strong>One-hundred and forty trials (51,749 patients) were included in the NMA. Considering the proportion of patients who achieve PASI90, ixekizumab showed the lowest NNT among all comparators (ixekizumab 2.01 [2.46-3.00]; risankizumab 2.05 [2.50-3-05]; guselkumab 2.16 [2.68-3.36]; secukinumab 2.40 [2.90-3.51]; brodalumab 2.61 [3.18-3.88]; ustekinumab 3.44 [4.12-4.95]; tildrakizumab 3.10 [4.15-5.59].</p><p><strong>Conclusion: </strong>The findings show that ixekizumab is the most effective option (NNT) for the treatment of moderate-to-severe plaque psoriasis.</p>","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":"8 ","pages":"53-57"},"PeriodicalIF":0.4000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3e/d3/grhta-8-53.PMC9616200.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global & Regional Health Technology Assessment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33393/grhta.2021.2222","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 2

Abstract

Background: Interleukin (IL) inhibitors achieve greater levels of efficacy than older systemic therapies. We calculated the number needed to treat (NNT) of ixekizumab compared with other IL inhibitors approved in Italy for the treatment of moderate-to-severe plaque psoriasis.

Methods: The clinical efficacy was evaluated in terms of NNT, based on the results of a recent network meta--analysis (NMA) by the Cochrane Database of Systematic Reviews. The NMA investigated many systemic and biological treatments, but this analysis compared only the efficacy of the following IL inhibitors - brodalumab, guselkumab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab - for patients with moderate-to-severe plaque psoriasis. Drugs were compared and ranked according to effectiveness considering the PASI (Psoriasis Area and Severity Index) 90 score.

Results: One-hundred and forty trials (51,749 patients) were included in the NMA. Considering the proportion of patients who achieve PASI90, ixekizumab showed the lowest NNT among all comparators (ixekizumab 2.01 [2.46-3.00]; risankizumab 2.05 [2.50-3-05]; guselkumab 2.16 [2.68-3.36]; secukinumab 2.40 [2.90-3.51]; brodalumab 2.61 [3.18-3.88]; ustekinumab 3.44 [4.12-4.95]; tildrakizumab 3.10 [4.15-5.59].

Conclusion: The findings show that ixekizumab is the most effective option (NNT) for the treatment of moderate-to-severe plaque psoriasis.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在意大利,白介素抑制剂被批准用于治疗中重度斑块型银屑病所需的治疗数量。
背景:白细胞介素(IL)抑制剂比老的全身疗法具有更高的疗效。我们计算了ixekizumab与意大利批准用于治疗中重度斑块型银屑病的其他IL抑制剂所需治疗的数量(NNT)。方法:根据Cochrane系统评价数据库(Cochrane Database of Systematic Reviews)最近的网络meta分析(NMA)结果,以NNT来评估临床疗效。NMA研究了许多系统和生物治疗,但该分析仅比较了以下IL抑制剂- brodalumab, guselkumab, ixekizumab, risankizumab, secukinumab, tildrakizumab和ustekinumab -对中度至重度斑块性银屑病患者的疗效。根据PASI(银屑病面积和严重程度指数)90分对药物进行疗效比较和排名。结果:140项试验(51,749例患者)被纳入NMA。考虑到达到PASI90的患者比例,ixekizumab在所有比较药中显示出最低的NNT (ixekizumab 2.01 [2.46-3.00];Risankizumab 2.05 [2.50-3-05];Guselkumab 2.16 [2.68-3.36];Secukinumab 2.40 [2.90-3.51];Brodalumab 2.61 [3.18-3.88];Ustekinumab 3.44 [4.12-4.95];Tildrakizumab 3.10[4.15-5.59]。结论:研究结果表明,ixekizumab是治疗中重度斑块型银屑病最有效的选择(NNT)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Global & Regional Health Technology Assessment
Global & Regional Health Technology Assessment HEALTH CARE SCIENCES & SERVICES-
CiteScore
0.80
自引率
20.00%
发文量
27
审稿时长
8 weeks
期刊介绍: Global & Regional Health Technology Assessment (GRHTA) is a peer-reviewed, open access journal which aims to promote health technology assessment and economic evaluation, enabling choices among alternative therapeutical paths or procedures with different clinical and economic outcomes. GRHTA is a unique journal having three different editorial boards who focus on their respective geographical expertise.
期刊最新文献
Analisi di costo-efficacia di brentuximab vedotin in combinazione con doxorubicina, vinblastina e dacarbazina (AVD) in pazienti adulti affetti da linfoma di Hodgkin in stadio IV. A 1-year per-patient cost of therapy administration analysis of mosunetuzumab and tisagenlecleucel in relapsed or refractory follicular lymphoma patients receiving two or more lines of systemic therapy. Impatto economico di dapagliflozin nella gestione della malattia renale cronica in Italia: risultati di un modello di micro-simulazione. Modello predittivo di policy per una migliore gestione della broncopneumopatia cronica ostruttiva: implicazioni economico-organizzative nel contesto sanitario italiano. A cost-effectiveness analysis of Navina Smart on adult patients affected by neurogenic bowel dysfunction.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1